Related Experiment Video
Updated: Aug 25, 2026

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions
Published on: October 17, 2017
Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation
I V Smirnova1, M Kajstura, T Sawamura
1Department of Medicine, New York Medical College, Valhalla, NY 10595, USA.
Abstract:
Intimal infiltration by monocytes and accumulation of lipids represent a critical step in the formation of fatty streaks during atherogenesis. Because elevated plasma levels of asymmetric dimethylarginine (ADMA), a potent nitric oxide (NO) synthase (NOS) inhibitor, are prevalent in diverse cardiovascular diseases, the goal of this study was to examine the contribution of NO deficiency to macrophage lipid accumulation. Inhibition of NO synthesis in PMA-primed human monocytic leukemia HL-60 cells resulted in a twofold increase in expression of the receptor for oxidized LDL (OxLDL), termed the lectin-like OxLDL receptor (LOX-1). Blockade of inducible NOS in activated macrophages resulted in 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI)-OxLDL accumulation and imparted macrophages with a foamy appearance as detected with oil-red O lipid staining. ADMA (15 microM) or N(G)-nitro-l-arginine methyl ester (l-NAME, 300 microM), both of which suppress inducible NOS activity, increased oil-red staining 1.9- and 2.8-fold, respectively. Macrophages treated with ADMA or l-NAME showed a 2.4-fold increase in accumulation of DiI-OxLDL. To examine the role of LOX-1 in this process, we used small interfering RNA (siRNA) duplex-mediated LOX-1 gene silencing. LOX-1 expression was suppressed twofold by siRNA as shown by Western blot analysis. This suppression was associated with a two- to fourfold decrease in DiI-OxLDL uptake as identified by fluorescence microscopy and decreased oil-red O staining by activated macrophages. In conclusion, accumulation of ADMA (a competitive inhibitor of NOS) in patients with chronic renal failure may be responsible for upregulation of LOX-1 receptor and increased OxLDL uptake, thus contributing to lipidosis and foam cell formation. The data illustrate an additional nonendothelial mode of antiatherogenic action of NO: prevention of LOX-1 induction and lipid accumulation by macrophages.
Insights
Nitric oxide (NO) deficiency, caused by elevated asymmetric dimethylarginine (ADMA), promotes macrophage lipid accumulation by upregulating the lectin-like oxidized LDL receptor (LOX-1). This NO deficiency contributes to foam cell formation, a key step in atherosclerosis.
Area of Science:
- Cardiovascular Research
- Atherosclerosis Pathogenesis
- Molecular Biology
Background:
- Elevated asymmetric dimethylarginine (ADMA) is linked to cardiovascular diseases.
- ADMA inhibits nitric oxide synthase (NOS), leading to NO deficiency.
- Macrophage lipid accumulation is a critical step in atherogenesis.
Purpose of the Study:
- To investigate the role of NO deficiency in macrophage lipid accumulation.
- To determine if NO deficiency contributes to the development of foam cells.
Main Methods:
- Inhibition of NO synthesis in human monocytic leukemia HL-60 cells.
- Treatment of activated macrophages with ADMA or N(G)-nitro-l-arginine methyl ester (l-NAME).
- Assessment of oxidized LDL (OxLDL) receptor (LOX-1) expression and DiI-OxLDL uptake.
- Gene silencing of LOX-1 using small interfering RNA (siRNA).
Main Results:
- Inhibition of NO synthesis increased LOX-1 expression and DiI-OxLDL accumulation in macrophages.
- ADMA and l-NAME treatment led to increased lipid staining and foamy appearance in macrophages.
- LOX-1 gene silencing reduced OxLDL uptake and lipid accumulation.
Conclusions:
- NO deficiency, potentially due to ADMA accumulation in chronic renal failure, upregulates LOX-1.
- Increased LOX-1 facilitates OxLDL uptake, contributing to macrophage lipidosis and foam cell formation.
- NO exerts a non-endothelial antiatherogenic effect by preventing LOX-1 induction and macrophage lipid accumulation.
Related Concept Videos
Inflammation
Coronary Artery Disease II: Pathophysiology
